Garry R. Cutting

发表

Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework

Steven E. Brenner, Xi Luo, Lea M. Starita, 2019, Genome Medicine.

Table 8. [Historical Classification Scheme for CFTR Pathogenic Variants].

Garry R. Cutting, Thida Ong, Susan G. Marshall, 2017 .

Cystic fibrosis genetics: from molecular understanding to clinical application

Garry R. Cutting, G. Cutting, 2014, Nature Reviews Genetics.

Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders

Garry R. Cutting, Edith Cheng, Darci L. Sternen, 2008, Genetics in Medicine.

Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA

Ronald G. Crystal, Garry R. Cutting, Bruce C. Trapnell, 1993, Nature Genetics.

Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2

Fred A. Wright, Fei Zou, Clayton W. Commander, 2011, Nature Genetics.

Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel

Victoria M. Pratt, Michael S. Watson, Wayne W. Grody, 2004, Genetics in Medicine.

A wearable potentiometric sensor with integrated salt bridge for sweat chloride measurement

Yi Li, Peter C. Searson, Garry R. Cutting, 2017 .

From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations

Garry R. Cutting, Harvey B. Pollard, Jeffrey L. Brodsky, 2016, Molecular biology of the cell.